Biotech entity
Every one of those 1 sits in a single category, pharma. Novo Nordisk A/S is most often covered alongside GLP-1, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Novo Nordisk A/S appears in 1 tracked Biotech story from August 10, 2026.
Last mentioned: Aug 10, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Novo Nordisk A/S is most often covered alongside GLP-1, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Novo Nordisk A/S appears in 1 tracked Biotech story from August 10, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 8 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Novo Nordisk A/S. Shared-story counts are live from our verified record — not editorial picks.
Novo Nordisk’s Q2 earnings reveal explosive uptake of its oral Wegovy pill, now commanding 90% of the U.S. oral obesity market with 267,000 weekly scripts. The therapy is expanding the GLP-1 market, with 80% of users being treatment-naïve, signaling a new era in obesity pharmacotherapy.
Source: tickerreport.com · finance.yahoo.com
Novo Nordisk A/S is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
